Extrawell Pharmaceutical Holdings Limited provided earnings guidance for the six months ended 30 September 2022. For the period, the Group expects to record a decline in profit of about HKD 44 million in the current period as compared with that for the six months ended 30 September 2021. The decline in profit was primarily attributable to a non-cash item, resulted from the decrease in a gain of about HKD 41 million arising from the fair value change of the financial assets at fair value through profit or loss i.e. the Group's investments in convertible bonds.

The Company is still in the process of preparing the interim results of the Group for the six months ended 30 September 2022, the information as set out above is only based on the preliminary assessment by the Board on the information currently available to it, including the Management Accounts, which have yet to be confirmed. The unaudited consolidated interim results of the Group for the six months ended 30 September 2022 are expected to be published before the end of November 2022.